Sandoz and Polpharma Biologics have become the first companies to get FDA approval for a biosimilar of Biogen's blockbuster multiple sclerosis therapy Tysabri, after overcoming a bid by Biogen to ...
Tysabri’s main US and European patents expired ... Pierre Bourdage, ad interim Global Head of Biopharmaceuticals at Sandoz, said: “Patient access to advanced medicines is important for all ...
hence the incidence of PML with Raptiva may be higher than with Tysabri (1 in 15,000). Michael Paranzino, head of the Psoriasis Cure Now of Kensington, Maryland, feels that banning Raptiva isn't ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback